secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-10-01T23:59:59+00:00
Accession:  0001140361-25-036875
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst completes sale of European ORLADEYO business; receives $250M upfront
-----------------------------------------------------------------------------

- Received $250M cash from sale of European ORLADEYO assets to Neopharmed Gentili; up to $14M in milestones.
- Transaction valued at ~5.4x trailing 12-month European ORLADEYO sales (through June 2025).
- Will use proceeds to retire $199M Pharmakon term loan, strengthening balance sheet.
- Reaffirms FY2025 revenue guidance of $580M–$600M, expects upper half excluding European revenue.
- European business was approximately breakeven; divestiture improves operating margin and focuses on U.S. core.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/0001140361-25-036875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000114036125036875/ef20056247_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-036875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer